nCounter® Breast Cancer 360™ Panel
Helping Your Research
Want a system that provides a unique 360° view of gene expression for the breast tumor, microenvironment, and immune response? If yes, then you have found the right product. The Human nCounter Breast Cancer 360 panel and data analysis report helps researchers quickly decode the complexities of breast cancer biology, develop novel breast cancer gene signatures, and categorize disease heterogeneity using 48 biological signatures including signatures based upon the validated PAM50 and Tumor Inflammation Signature (TIS) assays. Get the most out of your panel by quickly distilling a large amount of data into actionable signatures measuring variables crucial to breast tumor-immune interaction.
Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.
How It Works
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel pro
Find Your Panel
Product Information
Includes expertly curated 776 genes across 23 categories of breast cancer tumor biology to support the evaluation of pathways and process, as well as novel signature development.
Content included in the Breast Cancer 360 panel allows for a more comprehensive measurement of biological variables crucial to tumor progression and response to a wide range of treatments. Research signatures are enriched with potentially predictive genes involved in proliferation, endothelium, angiogenesis, cytotoxicity, stroma, inflammatory chemokines, and apoptosis.
- 48 signatures including two analytically validated signatures- PAM50 and Tumor Inflammation Signature
- 10 research-focused signatures and 30 novel signatures measuring important tumor and immune activities
- adapted to decode breast cancer biology in concert
Analytically Validated Signatures
PAM50 Signature1,2
Included with the Breast Cancer 360 panel is the PAM50 Signature. This 50-gene signature measures a gene expression profile that allows for the classification of breast cancer into four biologically distinct subtypes and a prognostic score.
- PAM50 Subtype
- Luminal A
- Luminal B
- HER2-Enriched
- Basal-like
- Prosigna Score / Risk of Recurrence
Tumor Inflammation Signature3
Included with the Breast Cancer 360 panel is the Tumor Inflammation Signature. This 18-gene signature measures activity known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade3.
- Includes 4 areas of immune biology used to determine peripherally suppressed immune response and the identification of “hot” or “cold” tumors
- Antigen Presenting Cells
- T Cell/NK presence
- IFNγ Biology
- T Cell Exhaustion
- Tissue-of-origin agnostic (Pan-cancer)
- Potential surrogate for PD-L1 and mutational load in research setting4
View publication and video.
360 Series Product Comparison
Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.
Publications
The prognostic value and molecular properties of tertiary lymphoid structures in oesophageal squamous cell carcinoma.
Background: Tertiary lymphoid structures (TLSs) play key roles in tumour adaptive immunity. However, the prognostic value and molecular properties of TLSs in oesophageal squamous cell carcinoma (ESCC) patients have not been studied.
Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.
While great strides have been made in the treatment of advanced renal cell carcinoma (RCC) with the emergence of immune checkpoint inhibitors (ICIs) and VEGFR-targeting drugs, sizable proportions of patients still do not respond to upfront therapy and long-term responses only occur in a minority of patients. There is therefore a great need for the development of better predictors of response and an increased understanding of mechanisms of resistance to these therapies.
The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis.
Brain metastases (BrMs) are a common occurrence in lung cancer with a dismal outcome. To understand the mechanism of metastasis to inform prognosis and treatment, here we analyze primary and metastasized tumor specimens from 44 non-small cell lung cancer patients by spatial RNA sequencing, affording a whole transcriptome map of metastasis resolved with morphological markers for the tumor core, tumor immune microenvironment (TIME), and tumor brain microenvironment (TBME).
Request a Quote
Contact our helpful experts and we’ll be in touch soon.
